Icahn boosts stake in Amylin Pharmaceuticals to 9.43%

By Lisa Kerner

Charlotte, N.C., Feb. 5 - Amylin Pharmaceuticals, Inc. investors led by Icahn Partners Master Fund LP bought 845,171 shares of the company's stock.

The shares were purchased on Jan. 30 and Feb. 2 for $11.3948 and $11.4675 per share, respectively, according to a schedule 13D/A filing with the Securities and Exchange Commission.

Carl Icahn investors beneficially own 12,971,328 shares, or 9.43%, of the San Diego biopharmaceutical company's common stock.

As previously reported, Icahn plans to nominate a slate of five directors for election to Amylin's board and to solicit proxies in favor of that slate after being unable to reach an agreement with the company regarding board representation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.